Ovarian cancer is the fifth most common cause of cancer death in women (1). Epithelial ovarian malignancies are the commonest (approximately 85%), with high grade serous carcinoma as the most frequent subtype. Overall 5-year survival rate for ovarian cancer is estimated to be 46% but it’s quite variable for the different stages estimated at about 90% for stage I, more 40% for stage II, almost 20% for stage III and around 5% for stage IV (2).

Although surgical staging based on the FIGO classification is the gold standard in ovarian cancer staging (3), patient management depends on the pre-surgical staging assessment, which is imaging-based. Imaging evaluation also may inform the feasibility of cytoreductive surgery and facilitates surgical planning.